Ares Capital, VICI Properties, Altria, and Pfizer provide robust, high-yield income streams that benefit significantly from the tax-free compounding environment of a Roth IRA.
Ares Capital's 9.76% yield, 17-year stable dividend history, and strong Q2 2026 core EPS coverage make it a compelling high-yield BDC for tax-advantaged accounts.
VICI Properties offers a 7.28% yield with 100% occupancy, 40-year CPI-linked leases, and a recent dividend increase, making it a durable net-lease REIT for Roth IRAs.
Altria's 6.16% yield, 60th dividend increase in 56 years, and strong smokeable margins support its status as a reliable income stock despite volume declines.
Pfizer's 6.22% yield, five consecutive EPS beats, and focus on dividend growth at a forward P/E of 10 present a deep-value pharma opportunity for tax-free compounding.
Investors seeking tax-efficient income can leverage Roth IRAs to hold high-yield assets like Ares Capital, VICI Properties, Altria, and Pfizer. These companies offer durable cash flows and consistent dividend growth, making them ideal for tax-advantaged accounts where ordinary income distributions would otherwise face high marginal tax rates.
These stocks pay distributions that are typically taxed as ordinary income. Holding them in a Roth IRA allows investors to avoid annual tax drag and benefit from tax-free compounding.